In all of the hubbub over New York’s legalization of adult-use (i.e. recreational cannabis), not a lot of ink has been spilled over the expansion of New York’s medical cannabis program. As a brief refresher, New York first legalized medical cannabis in 2016. Since then, only 10 organizations (ROs), have been issued registrations. We are proud to say that a few of them are clients of our law firm.
New York has had some of the more restrictive patient certification requirements nationwide, which resulted in lower revenue for the ROs. It was widely assumed that New York’s medical cannabis industry, in particular the existing ROs, would have a leg up on recreational applicants once the MRTA was finalized and passed. As we get into below, it turns out there may not have been as many advantages as the ROs expected.
Let’s go through some of the questions we most frequently get about the MRTA’s changes to New York’s medical cannabis program.
Who qualifies as an eligible patient?
Anyone who, “in the [patient’s physician’s] professional opinion and review of past treatments, the patient is likely to receive therapeutic or palliative benefits from the primary or adjunctive treatment with medical use of